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Summary. Background: Recently, stand-alone D-dimer testing at a positivity threshold of 750 lg L À1 has been proposed as a safe and efficient approach to rule out acute pulmonary embolism (PE), without additional imaging, but this approach needs validation. Objectives:
To evaluate stand-alone D-dimer testing at a positivity threshold of 750 lg L À1 to rule out PE. Methods: Individual data from 7268 patients with suspected PE previously enrolled in six prospective management studies were used. Patients were assessed by the Wells rule followed by quantitative D-dimer testing in those with a 'PE unlikely' score. Patients were classified post hoc as having a negative (< 750 lg L
À1
) or positive (≥ 750 lg L
) D-dimer. Using a one-stage meta-analytic approach, the negative predictive value (NPV) of stand-alone D-dimer testing was evaluated overall and in different risk subgroups. Results: The pooled incidence of PE was 23% (range, 13-42%). Overall, 44% of patients had a D-dimer
Introduction
Imaging tests are required to diagnose acute pulmonary embolism (PE) because signs and symptoms of PE are non-specific [1] . The most widely used techniques are computed tomography pulmonary angiography (CTPA) and ventilation-perfusion (V/Q) lung scanning, but both are costly, are time consuming and expose the patient to radiation. In addition, CTPA is associated with a risk of contrast-induced nephropathy. Many attempts have therefore been made to identify patients with suspected PE in whom the disease can be ruled out based on the combination of clinical decision rules and D-dimer testing without additional imaging.
Frequently used clinical decision rules in the diagnostic management of PE include the extensively validated Wells [2] and revised Geneva rules [3] , which classify patients according to the pretest probability of PE. If a patient is not at high risk of PE according to one of these rules, a D-dimer below 500 lg L À1 can safely rule out the diagnosis in about 20-30% of patients without additional imaging [4] .
An important next step to improve the diagnostic management of PE was the derivation of an age-adjusted D-dimer positivity threshold, which is defined as a patient's age times 10 lg L À1 in those older than 50 years [5] . By applying this threshold, the proportion of patients in whom imaging can be safely withheld is increased by another 5-6% [6, 7] . More recent advancements include the use of a variable D-dimer threshold according to the pretest probability assessment [8] , which is currently under investigation. The most recent attempt to further simplify the diagnostic management of PE and increase the proportion of patients in whom imaging can be withheld comes from Bates and colleagues, who prospectively evaluated D-dimer testing as a stand-alone test in 808 patients with suspected PE [9] . Imaging and anticoagulation were withheld in those with D-dimer levels below a fixed threshold of 750 lg L À1 . Thus, clinical probability assessment was not incorporated into the decision to refer the patient for imaging, which simplifies the diagnostic management and ensures reproducibility. Imaging could be withheld in more than half of patients, whereas only one patient with a D-dimer below 750 lg L À1 had venous thromboembolism (VTE) during 3-month follow-up. As acknowledged by the authors, this single-test approach needs external evaluation in other populations, especially in patients at higher risk of VTE. Therefore, the objective of the present study was to assess whether the safety and efficiency of stand-alone D-dimer testing at a positivity threshold of 750 lg L À1 to rule out PE could be confirmed or disproved using patient-level data from more than 7000 patients enrolled in previous management studies.
Methods
For the present analysis, we used combined data from six prospective management studies comprising a total of 7268 patients [10] [11] [12] [13] [14] [15] . These studies were previously identified by a systematic review and used for an individual patient data meta-analysis [6] .
Study selection
Briefly, MEDLINE and EMBASE were searched from 1 January 1998 to 13 February 2016 for PE diagnostic management studies that had prospectively enrolled consecutive, hemodynamically stable adults in secondary care, with signs and symptoms suggestive of acute PE. All patients had to be assessed by the dichotomous Wells rule, followed by quantitative D-dimer testing in those with a Wells score of 4 points or less ('PE unlikely').
Patients with a 'PE unlikely' Wells score and a normal D-dimer were to be managed without imaging, not given anticoagulants, and followed for 3 months for the occurrence of symptomatic VTE.
D-dimer testing D-dimer testing was performed using the locally available method, which could be a quantitative latex-based assay or an enzyme-linked immunosorbent assay. In total, five different, widely available D-dimer assays were used across the various studies. The conventional, fixed D-dimer positivity threshold of 500 lg L À1 was used in five studies [10, [12] [13] [14] [15] and an age-adjusted threshold was used in the remaining study [11] . The study protocols did not mandate D-dimer testing in patients with a Wells score above 4 points.
Statistical analysis
The analysis focused on the sensitivity, specificity and negative predictive value of D-dimer testing at a positivity threshold of 750 lg L
À1
. Patients were post-hoc classified as having a negative (< 750 lg
Because missing results can lead to biased results [16] , multiple imputation was used to replace missing D-dimer levels 10 times within each study separately. Results across the multiply imputed datasets were combined using Rubin's rule [17] . Sensitivity was defined as the number of patients with a positive D-dimer and PE at baseline or VTE during a 3-month follow-up period (true-positives), relative to all patients with PE at baseline or VTE during follow-up (true-positives plus false-negatives). Specificity was defined as the number of patients with a negative D-dimer without VTE (true-negatives) relative to all patients without VTE (true-negatives plus false-positives). The negative predictive value was defined as the number of patients with a negative D-dimer who did not have PE at baseline or during follow-up (true-negatives) relative to all patients with a negative D-dimer (true-negatives plus false-negatives). The sensitivity, specificity and negative predictive value with 95% confidence intervals (CIs) were estimated using generalized linear mixed-effects models in a onestage meta-analytic approach. Because observations within a study are more similar than observations between studies, a study-specific random effect was specified to account for this clustering [18] . Proportions and 95% CIs were calculated using the intercept of each model. To assess between-study heterogeneity, 90% prediction intervals (PIs) were calculated around the estimates [18] .
Sensitivity, specificity, negative likelihood ratio and negative predictive value were calculated for the whole study group. Sensitivity, specificity and negative predictive value were also calculated in patients with a low, moderate and high clinical pretest probability according to the Wells score, as well as in those with active cancer, those with previous VTE and inpatients. Because test characteristics may vary by the pretest probability, we also evaluated the performance of D-dimer testing in a low-risk group comprised of outpatients without cancer or previous VTE as well as in an analysis in which the REPEAD study (PE prevalence, 42%) was left out.
All analyses were performed in R, version 3.3.0 (R Foundation for Statistical Computing, Vienna, Austria, www.R-project.org), using the mice package, version 2.22, for multiple imputation and the lme4 package, version 1.1-12, for the generalized linear mixed-effects models.
Results and discussion
The study group comprised 7268 patients enrolled in six studies [10] [11] [12] [13] [14] [15] . The mean age was 56 years and 58% were female. The incidence of PE ranged from 13% to 42% across the studies. Overall, PE was diagnosed in 1527 patients (pooled prevalence, 23%; 95% CI, 17-30%; 90% PI, 9.3-46). Baseline characteristics are summarized in Table 1 . Quantitative D-dimer levels were missing in 995 patients (14%) for whom multiple imputation was used. These patients were older (age 58.6 vs. 56.1 years), had a higher median Wells score (4.5 vs. 3 points) and were more often classified as 'PE likely' (90% vs. 18%) than patients with available D-dimer test results.
Overall, the proportion of patients in whom imaging could have been withheld based on a D-dimer below 750 lg L À1 was 44% (95% CI, 36-52%; 90% PI, Table 2) . The results from the present analysis suggest that stand-alone D-dimer testing at a fixed positivity threshold of 750 lg L À1 is not safe to rule out PE in populations with a higher incidence of PE (i.e. about 20% or more) or in higher risk patients, such as those with active cancer, those with previous VTE, inpatients or those with a moderate or high clinical probability of PE according to the Wells score. A lower limit of the 95% CI of the negative predictive value of 97% is commonly accepted as a safe margin, because even pulmonary angiography, which is considered the reference standard, cannot detect all cases [19] . Overall, we observed a negative predictive value of 97.2% with the lower limit of the 95% CI exceeding 97%, hence not excluding the possibility of a negative predictive value of less than 97%. In high-risk patients, the negative predictive value was even lower, with point estimates ranging from 79.3% in patients with a high probability of PE on the Wells score to 96.2% in cancer patients. This means that in the former group one out of every five patients with a D-dimer below 750 lg L À1 was diagnosed with symptomatic VTE. The lower negative predictive values observed in the present analysis compared with the study by Bates and colleagues may reflect differences in patient populations. Although the proportions of patients with active cancer, patients with previous VTE and inpatients were comparable, 72% of patients in the study by Bates and colleagues had a low pretest probability of PE, compared with 39% in our dataset. Moreover, only 58 patients with high probability of PE were included in the study by Bates and colleagues, compared with 293 in the present Low probability, n (%) 2852 (39) Moderate probability, n (%) 4061 (56) High probability, n (%) 293 (4) Missing, n (%) analysis. In addition, the incidence of PE was lower in the Canadian study (13%) than in the present analysis comprising European studies only (23%). Because the test characteristics of D-dimer can vary with the pretest probability of PE, we also evaluated the performance of D-dimer as a stand-alone test in patients with a lower risk of PE. Similar to the study by Bates and colleagues, the results from these sensitivity analyses suggest that use of D-dimer in a single-test approach may in fact be safe and efficient in these groups. However, such an approach would require a pretest PE risk assessment in a healthcare setting with a higher incidence of PE, which is identical to the currently recommended diagnostic algorithms consisting of a clinical decision rule and quantitative D-dimer testing.
24-66%
Strengths of our analysis include the large number of patients with suspected PE, which allows for more precise estimates and robust subgroup analysis. Our study also has some limitations. This was a post-hoc analysis of combined data from six studies. As a consequence, a substantial proportion of patients with a D-dimer below 750 lg L À1 underwent imaging, potentially resulting in detection of clots with less clinical significance. As a consequence, the negative predictive value may have been somewhat underestimated, because a number of these patients may have had a favorable prognosis if left untreated. However, at least 34% of patients with a falsenegative D-dimer between 500 and 750 lg L À1 had a segmental or more proximal PE at baseline or symptomatic VTE during follow-up based on previously published data [20] (data not shown), which indicates that it is unlikely that these clots are clinically irrelevant. D-dimer levels were missing in 14% of patients. However, multiple imputation was used to minimize bias associated with missing data and, reassuringly, the complete case analysis yielded comparable results to the imputed data. Five different, widely available D-dimer assays were used in the studies. Because patient-level information on the use of D-dimer assay was not available, results could not be stratified by assay. Finally, considerable heterogeneity in the incidence of PE was observed across the studies.
Although the performance of D-dimer testing was evaluated in several subgroup and sensitivity analyses, which all supported the main conclusions, our findings require confirmation. Taken together, our findings suggest that stand-alone D-dimer testing at a positivity threshold of 750 lg L À1 cannot safely rule out PE in patients at higher risk of PE, such as those with a moderate or high probability of PE according to the Wells rule, active cancer or previous VTE, or inpatients, or in settings with a high incidence of PE. This analysis does not support the use of stand-alone D-dimer testing in clinical practice. Although this approach may be reasonable in low-risk patients, it remains unclear how these patients should be selected prior to D-dimer testing. 
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